One post from Jaban M Moore's dossier. This page reviews a single piece of material. The full dossier cross-checks 42 materials and carries the verified credential and scope verdicts.
Read the full dossier →/api/archive/snapshots/e68817f9a94fa09928d7e12f993e54645f8538c03666bd53bfd50804f64c7eab/page.html
View dossier →Jaban M Moore alias The Hidden-Lab Hustler
YouTube · UCgCDI1l6SF-q_wNG8czQ0nA
Practice location
420 ARMOUR RD
NORTH KANSAS CITY, MO 64116
Funnel-first framing that runs on persuasion, light on published evidence.
- Of 16 health claims, 12 run counter to or conflict with the published evidence, and 3 were not independently checked.
- Primary persuasion tactic: Normal labs become proof of hidden disease.
- Stated credentials look inflated relative to the advice given.
- Profits from the products and labs they recommend, with no clear disclosure.
- Gives advice beyond what their license covers.
Jaban Moore serves the classic doc-bro tasting menu: ordinary lab results are recast as sinister omissions, a coaching guest supplies borrowed certainty, and the cure is conveniently one booking call away. Nothing says metabolic liberation like making your bloodwork fail an audition for the sales funnel.
High grift signals
Score breakdown
Direct answer
Jaban M Moore is licensed in Missouri as a chiropractor (DC), not as an MD or DO, and Missouri's chiropractic scope statute (RSMo 331.010(1)) limits that license to musculoskeletal care, not the diagnosis or treatment of systemic disease. Even so, they advertise diagnosing or treating Hashimoto's, H. pylori, Leaky gut, Hormone imbalance, and Cortisol and weight gain, conditions that belong with endocrinologists and gastroenterologists. Those same pages route patients toward lab panels and paid programs that Jaban M Moore profits from.
Key findings
- Fear Mongering: The wording turns an ordinary negative or reassuring evaluation into evidence that the patient is secretly abnormal, encouraging distrust of clinicians and pursuit of more testing.see section ↓
- Claim "Nine additional laboratory tests explain why women's bodies stop responding to weight-los…": not supported by peer-reviewed evidence.see section ↓
- Claim "A gut-hormone connection that ordinary doctors were not trained to recognize explains the…": not supported by peer-reviewed evidence.see section ↓
- NPI registry confirms Jaban Moore as Chiropractor (DC) in Missouri (NPI 1073958815).see section ↓
- Jaban M Moore shows credential inflation relative to stated vs likely credentials.see section ↓
- Dr Jaban M Moore is marketed with a doctor title, but reviewed credentials indicate Chiropractor (DC) rather than an MD/DO physician license.see section ↓
- Against Missouri State Board of Chiropractic Examiners scope rules (RSMo 331.010(1)), these advertised activities appear outside Jaban M Moore's license (including conditions they merely list as ones they treat): H. pylori, leaky gut, and Hashimoto's almost always occur together., Treating H.…see section ↓
- 15 of 15 advertised activities fall outside permitted Chiropractor scope in MO.see section ↓
Claims & evidence
15 advertised conditions or treatments fall outside their license scope. Each box leads with state-board scope notation; literature cross-check follows when we matched a specific claim. Every card carries its receipts: the quoted wording, a live source link, and an archived copy.
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure H. pylori, leaky gut, and Hashimoto's almost always occur together..
H. pylori, leaky gut, and Hashimoto's almost always occur together.
- Supports
- Some observational studies and meta-analyses report an association between H. pylori infection and autoimmune thyroid disease, although results are inconsistent and the association is weaker or nonsignificant in some Hashimoto-specific analyses. [2][4][5][7][8][10][11][12] A meta-analysis found no statistically significant association between H. [9] pylori and Hashimoto thyroiditis specifically (OR 1. [3] 45, 95% CI 0. 92–2. 26). Reviews of Hashimoto thyroiditis describe possible alterations in gut microbiota and intestinal permeability, but these findings do not establish that clinically defined “leaky gut” commonly co-occurs with Hashimoto’s. [6]
- Contradicts
- The claim says the three conditions almost always occur together, but the cited and searched evidence does not show near-universal co-occurrence or prevalence of the combination. [6] A large population-based study of autoimmune disorders addresses co-occurrence among autoimmune diseases, not a near-universal triad involving H. [2] pylori and intestinal permeability. Standard Hashimoto reviews describe Hashimoto thyroiditis as an autoimmune thyroid disorder without identifying H. [3][4][7] pylori infection or “leaky gut” as almost invariably present. Evidence for gut permeability is largely observational, uses indirect biomarkers or selected patient samples, and does not establish that “leaky gut” is a consistently defined clinical diagnosis. Associations between H. pylori and Hashimoto’s are conflicting: one meta-analysis found a significant association for autoimmune thyroid disease overall but not Hashimoto’s specifically. [5][8][9][10][11][12] Therefore, even possible associations between individual pairs cannot support the stated near-universal three-way relationship.
- Mainstream view
- Hashimoto thyroiditis, H. [3][6][7] pylori infection, and increased intestinal permeability are distinct phenomena. [11][12] Research suggests possible associations between H. pylori or gut-microbiome changes and autoimmune thyroid disease, but causality, clinical significance, and the frequency of their joint occurrence remain uncertain. [2][4][5][8][9][10] The mainstream medical view is that these conditions do not almost always occur together, and routine diagnosis or treatment of H. pylori or presumed “leaky gut” is not justified solely because a person has Hashimoto’s.
“How H. pylori, leaky gut, and Hashimoto's almost always appear together”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Treating H. pylori, leaky gut, and Hashimoto's together is necessary to resolve being stuck with weight loss..
Treating H. pylori, leaky gut, and Hashimoto's together is necessary to resolve being stuck with weight loss.
- Supports
- Treating confirmed H. pylori infection is recommended for its established gastric indications, but available evidence does not show that it is necessary to overcome difficulty losing weight. [17] A placebo-controlled randomized trial found that eradication slightly increased, rather than reduced, body weight and BMI. [13][20] A systematic review and meta-analysis reported an association between H. [18] pylori infection and overweight, but this was observational evidence and does not establish that eradication enables weight loss. [15][16][21] Clinical-trial evidence on probiotics, prebiotics, and intestinal-permeability markers does not demonstrate that treating a broadly defined “leaky gut” causes clinically meaningful weight loss; the reported evidence is heterogeneous and often low certainty. [19] Hashimoto thyroiditis can contribute to weight changes when hypothyroidism is present, and treating documented hypothyroidism is appropriate, but no evidence supports treating Hashimoto’s itself as part of a required combined protocol for weight loss.
- Contradicts
- A Mendelian-randomization study and meta-analysis found no clinically relevant association between H. [15][18][19] pylori colonization and BMI or obesity and no evidence of a causal relationship. [16][17][20] Another clinical study found no significant BMI difference after H. pylori eradication compared with non-eradication. [21] Weight-loss research more commonly finds that reductions in intestinal permeability occur alongside weight loss, which does not establish that intestinal permeability is the cause or that treating it is required to produce weight loss. The supplied index results are openFDA enforcement records rather than peer-reviewed clinical evidence and do not support this claim. [13] There are no high-quality trials showing that simultaneously treating H. pylori, “leaky gut,” and Hashimoto’s is necessary or reliably resolves being stuck with weight loss.
- Mainstream view
- The mainstream medical approach is to test and treat confirmed H. [20] pylori infection according to gastrointestinal guidelines, diagnose and treat overt hypothyroidism with thyroid hormone replacement, and evaluate difficulty losing weight using evidence-based assessment of calorie intake, medications, sleep, activity, endocrine disorders, and other relevant conditions. [13][15][16][17][21] “Leaky gut” is not a broadly established diagnosis with a validated treatment protocol for routine weight-loss management. Treating all three conditions together is not considered necessary, and treatment should be directed at individually confirmed disorders rather than an influencer-defined combination.
“why treating one without the others keeps women stuck”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Hashimoto's.
Hashimoto's
- Supports
- Some observational studies and meta-analyses report an association between H. pylori infection and autoimmune thyroid disease, although results are inconsistent and the association is weaker or nonsignificant in some Hashimoto-specific analyses. [2][4][5][7][8][10][11][12] A meta-analysis found no statistically significant association between H. [9] pylori and Hashimoto thyroiditis specifically (OR 1. [3] 45, 95% CI 0. 92–2. 26). Reviews of Hashimoto thyroiditis describe possible alterations in gut microbiota and intestinal permeability, but these findings do not establish that clinically defined “leaky gut” commonly co-occurs with Hashimoto’s. [6]
- Contradicts
- The claim says the three conditions almost always occur together, but the cited and searched evidence does not show near-universal co-occurrence or prevalence of the combination. [6] A large population-based study of autoimmune disorders addresses co-occurrence among autoimmune diseases, not a near-universal triad involving H. [2] pylori and intestinal permeability. Standard Hashimoto reviews describe Hashimoto thyroiditis as an autoimmune thyroid disorder without identifying H. [3][4][7] pylori infection or “leaky gut” as almost invariably present. Evidence for gut permeability is largely observational, uses indirect biomarkers or selected patient samples, and does not establish that “leaky gut” is a consistently defined clinical diagnosis. Associations between H. pylori and Hashimoto’s are conflicting: one meta-analysis found a significant association for autoimmune thyroid disease overall but not Hashimoto’s specifically. [5][8][9][10][11][12] Therefore, even possible associations between individual pairs cannot support the stated near-universal three-way relationship.
- Mainstream view
- Hashimoto thyroiditis, H. [3][6][7] pylori infection, and increased intestinal permeability are distinct phenomena. [11][12] Research suggests possible associations between H. pylori or gut-microbiome changes and autoimmune thyroid disease, but causality, clinical significance, and the frequency of their joint occurrence remain uncertain. [2][4][5][8][9][10] The mainstream medical view is that these conditions do not almost always occur together, and routine diagnosis or treatment of H. pylori or presumed “leaky gut” is not justified solely because a person has Hashimoto’s.
“Hashimoto's”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure H. pylori.
H. pylori
- Supports
- Some observational studies and meta-analyses report an association between H. pylori infection and autoimmune thyroid disease, although results are inconsistent and the association is weaker or nonsignificant in some Hashimoto-specific analyses. [2][4][5][7][8][10][11][12] A meta-analysis found no statistically significant association between H. [9] pylori and Hashimoto thyroiditis specifically (OR 1. [3] 45, 95% CI 0. 92–2. 26). Reviews of Hashimoto thyroiditis describe possible alterations in gut microbiota and intestinal permeability, but these findings do not establish that clinically defined “leaky gut” commonly co-occurs with Hashimoto’s. [6]
- Contradicts
- The claim says the three conditions almost always occur together, but the cited and searched evidence does not show near-universal co-occurrence or prevalence of the combination. [6] A large population-based study of autoimmune disorders addresses co-occurrence among autoimmune diseases, not a near-universal triad involving H. [2] pylori and intestinal permeability. Standard Hashimoto reviews describe Hashimoto thyroiditis as an autoimmune thyroid disorder without identifying H. [3][4][7] pylori infection or “leaky gut” as almost invariably present. Evidence for gut permeability is largely observational, uses indirect biomarkers or selected patient samples, and does not establish that “leaky gut” is a consistently defined clinical diagnosis. Associations between H. pylori and Hashimoto’s are conflicting: one meta-analysis found a significant association for autoimmune thyroid disease overall but not Hashimoto’s specifically. [5][8][9][10][11][12] Therefore, even possible associations between individual pairs cannot support the stated near-universal three-way relationship.
- Mainstream view
- Hashimoto thyroiditis, H. [3][6][7] pylori infection, and increased intestinal permeability are distinct phenomena. [11][12] Research suggests possible associations between H. pylori or gut-microbiome changes and autoimmune thyroid disease, but causality, clinical significance, and the frequency of their joint occurrence remain uncertain. [2][4][5][8][9][10] The mainstream medical view is that these conditions do not almost always occur together, and routine diagnosis or treatment of H. pylori or presumed “leaky gut” is not justified solely because a person has Hashimoto’s.
“H pylori”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Leaky gut.
Leaky gut
- Supports
- Some observational studies and meta-analyses report an association between H. pylori infection and autoimmune thyroid disease, although results are inconsistent and the association is weaker or nonsignificant in some Hashimoto-specific analyses. [2][4][5][7][8][10][11][12] A meta-analysis found no statistically significant association between H. [9] pylori and Hashimoto thyroiditis specifically (OR 1. [3] 45, 95% CI 0. 92–2. 26). Reviews of Hashimoto thyroiditis describe possible alterations in gut microbiota and intestinal permeability, but these findings do not establish that clinically defined “leaky gut” commonly co-occurs with Hashimoto’s. [6]
- Contradicts
- The claim says the three conditions almost always occur together, but the cited and searched evidence does not show near-universal co-occurrence or prevalence of the combination. [6] A large population-based study of autoimmune disorders addresses co-occurrence among autoimmune diseases, not a near-universal triad involving H. [2] pylori and intestinal permeability. Standard Hashimoto reviews describe Hashimoto thyroiditis as an autoimmune thyroid disorder without identifying H. [3][4][7] pylori infection or “leaky gut” as almost invariably present. Evidence for gut permeability is largely observational, uses indirect biomarkers or selected patient samples, and does not establish that “leaky gut” is a consistently defined clinical diagnosis. Associations between H. pylori and Hashimoto’s are conflicting: one meta-analysis found a significant association for autoimmune thyroid disease overall but not Hashimoto’s specifically. [5][8][9][10][11][12] Therefore, even possible associations between individual pairs cannot support the stated near-universal three-way relationship.
- Mainstream view
- Hashimoto thyroiditis, H. [3][6][7] pylori infection, and increased intestinal permeability are distinct phenomena. [11][12] Research suggests possible associations between H. pylori or gut-microbiome changes and autoimmune thyroid disease, but causality, clinical significance, and the frequency of their joint occurrence remain uncertain. [2][4][5][8][9][10] The mainstream medical view is that these conditions do not almost always occur together, and routine diagnosis or treatment of H. pylori or presumed “leaky gut” is not justified solely because a person has Hashimoto’s.
“leaky gut”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Hormone imbalance.
Hormone imbalance
- Supports
- Licensed hormone treatments are evidence-based for specific, diagnosed endocrine conditions and indications, such as hypopituitarism, menopause-related vasomotor or genitourinary symptoms, osteoporosis prevention, and confirmed hypogonadism; treatment requires individualized prescribing and monitoring. [23][25][31] The Endocrine Society provides evidence-based recommendations for hormone replacement in adults with hypopituitarism. [30][32][33] Menopausal hormone therapy is effective for appropriately selected symptomatic patients, particularly those younger than 60 years or within 10 years of menopause onset.
- Contradicts
- The phrase hormone imbalance is nonspecific and does not establish a diagnosis, causal mechanism, treatment, or outcome. [29][31] The listed papers do not directly validate a general licensed treatment for hormone imbalance. In particular, the guideline on androgen therapy advises against diagnosing androgen deficiency in otherwise healthy women and against routine testosterone or DHEA use for general well-being or nonspecific symptoms because efficacy and long-term safety are insufficient. [25][30][32][33] Several index papers concern unrelated topics, including plant immunity, sarcopenia, osteoporosis therapies, gynecomastia, pregnancy safety, and vasopressin hypotheses, and therefore do not support the broad claim. [23][26][27][28]
- Mainstream view
- There is no single medical condition called hormone imbalance. Clinicians should identify the specific hormone, confirm an appropriate diagnosis with clinical assessment and validated testing when indicated, determine the underlying cause, and use an approved treatment only when its benefits and risks are established for that condition. [23][25][28][30][31][32][33] Broad promises to treat hormone imbalance without naming the diagnosis, therapy, or outcome are not medically assessable as a general claim.
“hormone imbalance”
Rule: RSMo 331.010(1)
See every doc bro advertising Hormone imbalance and replacement
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Cortisol and weight gain as within their scope of practice.
Cortisol and weight gain
- Supports
- Licensed medical treatment exists for confirmed cortisol excess, especially Cushing syndrome. [34][36] Endocrine Society guidance recommends normalizing cortisol or its receptor action and treating associated complications; surgery to remove the causative lesion is generally first-line, with medications used when surgery is not possible, unsuccessful, or as interim treatment. [35][37] Cushing syndrome commonly includes central weight gain and obesity, so treating confirmed hypercortisolism may improve weight-related manifestations, although weight outcomes vary and are not guaranteed.
- Contradicts
- The claim is too fragmentary to establish that cortisol treatment is appropriate for ordinary weight gain, stress-related cortisol changes, or obesity without diagnosed hypercortisolism. Guidelines specifically recommend against lowering cortisol or blocking its action when Cushing syndrome has not been established. [34][35][36][37] The supplied index records are unrelated clinical trials and provide no direct evidence for cortisol treatment or weight gain; the glycemic-monitoring study , rheumatoid-arthritis exercise study , angioplasty study , educational study , heart-failure device study , mHealth study , training study , and SCENAR neck-pain study do not support this claim.
- Mainstream view
- Cortisol-directed treatment is evidence-based for biochemically confirmed Cushing syndrome or another defined disorder of cortisol excess, under specialist medical care. [34][35][36][37] Diagnosis requires appropriate biochemical testing and evaluation of the cause; nonspecific weight gain alone does not justify cortisol-lowering treatment. For typical obesity or unexplained weight gain, management should address established causes and evidence-based weight-management interventions rather than presumed cortisol excess.
“cortisol and weight gain”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Normal standard bloodwork means the doctor ran the wrong tests and the patient is not normal. as within their scope of practice.
Normal standard bloodwork means the doctor ran the wrong tests and the patient is not normal.
- Supports
- Normal standard bloodwork does not exclude every disease, because tests have limited sensitivity and must be selected according to the clinical question; a normal result can occur despite disease. [38][40] Reference intervals are statistical comparators, not absolute definitions of health, and should be interpreted in the context of symptoms, examination, history, and pretest probability.
- Contradicts
- The claim overstates this limitation by asserting that normal results mean the wrong tests were run and that the patient is not normal. [38][40][41] Standard blood tests may be appropriate and clinically reassuring when matched to the patient’s presentation, and indiscriminate additional testing can produce false positives, unnecessary investigations, and harm. [39] The supplied index papers are ClinicalTrials. gov records concerning unrelated interventions and do not provide evidence for this claim.
- Mainstream view
- Normal standard bloodwork means that the tested abnormalities are not detected within the tests’ limits; it does not prove that a person has no disease, nor does it imply that the clinician chose the wrong tests or that the patient is inherently abnormal. [38][41] Further evaluation is warranted when symptoms, examination findings, risk factors, or clinical suspicion indicate a specific condition requiring targeted testing.
“She's not normal. Her doctor just ran the wrong tests.”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Nine additional laboratory tests explain why women's bodies stop responding to weight-loss efforts when standard bloodwork does not. as within their scope of practice.
Nine additional laboratory tests explain why women's bodies stop responding to weight-loss efforts when standard bloodwork does not.
- Supports
- Guidelines support targeted additional testing when symptoms or examination suggest a specific disorder, such as menstrual irregularity or hyperandrogenism suggesting PCOS, or characteristic features suggesting Cushing syndrome. The PCOS guideline recommends tests including TSH, prolactin, and 17-hydroxyprogesterone to exclude mimicking disorders, and glucose testing to assess metabolic risk. [43][44][45] Obesity guidelines describe a broader possible assessment including glucose, lipids, liver and kidney function, thyroid testing, and selected endocrine tests, but state that endocrine investigations should be clinically indicated rather than universally applied.
- Contradicts
- No cited paper directly demonstrates that nine additional laboratory tests explain why women's bodies stop responding to weight-loss efforts after standard bloodwork is normal. The European endocrine guideline recommends thyroid testing in obesity but reserves testing for hypercortisolism and female gonadal dysfunction for patients with clinical suspicion, and does not recommend routine testing of several other hormones or vitamin D. [43] Evidence that metabolic adaptation can occur after weight loss does not establish that a panel of nine laboratory tests identifies its cause or restores weight loss; other evidence finds resting-metabolic-rate adaptation to be minor and not sustained long term with weight regain. [44][45] The indexed telephone weight-loss meta-analysis concerns delivery of an intervention, not diagnostic laboratory testing. [42] The indexed GLP-1 review records are reviews of a pharmacologic treatment question and do not support the claimed diagnostic panel.
- Mainstream view
- Weight-loss plateaus and apparent resistance are multifactorial and should be assessed through history, medications, dietary and activity factors, sleep, mental health, anthropometrics, comorbidities, and adherence, with standard metabolic testing and targeted endocrine or reproductive testing when clinical features warrant it. [43][44][45] There is no mainstream recommendation for nine extra laboratory tests for all women whose standard bloodwork is normal, and normal routine results do not by themselves establish a hidden laboratory explanation.
“the 9 lab tests that finally explain why”
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure A gut-hormone connection that ordinary doctors were not trained to recognize explains these health challenges..
A gut-hormone connection that ordinary doctors were not trained to recognize explains these health challenges.
- Supports
- The gastrointestinal tract has well-established sensory and endocrine signaling systems that communicate with the nervous system and regulate digestion, appetite, glucose metabolism, and other physiological processes. [56] Sensory neurons detect mechanical stretch and nutrients in the digestive system, providing a biological basis for gut-to-brain signaling. [47][49][54][55][57] Gut chemosensing and enteroendocrine signaling are recognized areas of research with potential relevance to disease mechanisms. [48] Gut hormones such as GLP-1, GIP, and PYY have established roles in appetite and glucose regulation, and pharmacologic agonists are clinically used for obesity and type 2 diabetes. [50] The indexed papers therefore support the existence and medical relevance of gut-hormone and gut-brain connections.
- Contradicts
- The claim is too broad to establish that this connection explains unspecified health challenges. [51] The indexed papers are primarily reviews or mechanistic studies and do not demonstrate that a single gut-hormone connection accounts for particular symptoms or diseases. [47] Evidence connecting gut-brain mechanisms to depression, obesity, puberty, cardiometabolic disease, or post-bariatric changes is complex and condition-specific rather than a universal explanation. [50] The assertion that ordinary doctors were not trained to recognize the connection is unsupported by the cited literature and is misleading: gastrointestinal endocrine signaling and the brain-gut axis are recognized components of contemporary physiology and clinical medicine. [49][54][55][56][57] Even where gut-brain or microbiome mechanisms are biologically plausible, human clinical evidence for many proposed disease explanations and interventions remains limited, observational, or preclinical. [48]
- Mainstream view
- Gut hormones and bidirectional gut-brain signaling are legitimate, established areas of physiology, and some gut-hormone pathways have clear clinical applications, especially GLP-1-based treatment for diabetes and obesity. [48][49][50][54][55][56][57] However, these pathways do not provide a generalized explanation for unspecified health challenges, and claims that conventional physicians are broadly unaware of them are not evidence-based. [47] Interpretation should be disease-specific and grounded in validated diagnoses, established treatments, and human clinical evidence.
“The gut-hormone connection your doctor was never trained to see”
Rule: RSMo 331.010(1)
See every doc bro advertising Hormone imbalance and replacement
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Women's hormones.
Women's hormones
- Supports
- Licensed hormone treatments exist for specific indications, including menopausal vasomotor symptoms, genitourinary symptoms, prevention of bone loss, and treatment of hypoestrogenism. [68] Menopausal hormone therapy is generally effective for bothersome vasomotor symptoms in appropriately selected women, particularly those younger than 60 or within 10 years of menopause, after individualized risk assessment. [59][67][69] The Lancet Commission emphasizes comprehensive cardiovascular risk reduction in women, but does not establish hormone treatment as a universal therapy for women's health. [58][65]
- Contradicts
- The phrase licensed treatment of Women's hormones is too vague to establish a specific treatment, diagnosis, indication, mechanism, or outcome. [69] Hormone therapy is not a general treatment for all women's hormonal concerns, and it is not routinely recommended to prevent cardiovascular disease, dementia, or other nonspecific health outcomes. [58][59][60][65][67] Benefits and risks vary by age, menopausal timing, formulation, route, dose, uterine status, and medical history. [61][68] Transdermal estradiol dosing must be individualized rather than promoted as a universally appropriate treatment. The listed papers on infertility, insulin sensitivity, breast cancer treatment, and GPER biology concern specific conditions or mechanisms and do not validate a generic licensed treatment for women's hormones. [62][63][64]
- Mainstream view
- Licensed hormonal therapies are evidence-based treatments for defined conditions, especially menopausal symptoms and selected cases of premature ovarian insufficiency or hypoestrogenism, when prescribed and monitored by a qualified clinician. [67][68] They are not a single general treatment for women's hormones; diagnosis, treatment choice, contraindication screening, shared decision-making, and periodic reassessment are required. [58][59] The claim as stated is too fragmentary and nonspecific to evaluate as a substantive medical claim. [65][69]
“women's hormones”
Rule: RSMo 331.010(1)
See every doc bro advertising Hormone imbalance and replacement
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Weight loss resistance.
Weight loss resistance
- Supports
- Licensed medications are evidence-based options for obesity or overweight with weight-related complications, particularly when lifestyle treatment alone is insufficient; major guidelines recommend agents such as semaglutide, tirzepatide, liraglutide, or other approved therapies at specified BMI thresholds. [78][79][80] The index review describes advances in anti-obesity drug development but does not establish a licensed treatment specifically for a condition called weight-loss resistance. [70][81] Tirzepatide has potential relevance to metabolic disorders including polycystic ovary syndrome, but this review is not evidence that it treats weight-loss resistance as a defined condition. [71]
- Contradicts
- Weight-loss resistance is not established here as a specific licensed diagnosis, and the supplied papers do not show that any treatment is licensed for it. [71] The remaining index papers concern longevity diets, a plant-based diet in myeloma precursor disorders, mouse multi-agonists, cancer biology, mouse GIPR pharmacology, and experimental lipodystrophy strategies; they do not provide direct clinical evidence for licensed treatment of weight-loss resistance. [72][73][74][77][81] Current guidance licenses and recommends treatments for obesity or qualifying overweight based on BMI, comorbidities, and clinical response, not for the vague label weight-loss resistance. [70][78][79][80]
- Mainstream view
- Clinicians assess causes of inadequate weight loss or regain and may use approved obesity medications alongside nutrition, physical activity, and behavioral care when BMI is at least 30 kg/m² or at least 27 kg/m² with an obesity-related complication. [70][74][75][78][80] This does not amount to a licensed treatment indication for weight-loss resistance as stated. The claim is therefore unsupported. [81]
“weight loss resistance”
Rule: RSMo 331.010(1)
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Gut health.
Gut health
- Supports
- Licensed, evidence-based treatments exist for specific gastrointestinal diseases, including medications, dietary interventions, and selected microbiota-based therapies. [91] The AGA recommends fecal microbiota-based therapies for selected adults with recurrent or severe Clostridioides difficile infection, but not routinely for inflammatory bowel disease or irritable bowel syndrome outside clinical trials. [83][89][90][92][93] Some specific probiotic strains may help in narrowly defined conditions such as prevention of antibiotic-associated diarrhea, but benefits are strain- and disease-specific. The index papers provide indirect support that diet, lifestyle, inflammation, and the gut microbiome can influence health, including associations between ultra-processed food exposure and adverse outcomes and inflammatory or immune dysfunction in Parkinson disease . [82][84][85][86]
- Contradicts
- The phrase licensed treatment of Gut health is not a defined medical indication, and the cited papers do not establish a single licensed intervention that generally treats or improves gut health. [82][91] The evidence does not support broad claims that probiotics, microbiome manipulation, fasting, or lifestyle programs universally restore gut health. [90][93] AGA guidance recommends against routine fecal microbiota transplantation for inflammatory bowel disease or irritable bowel syndrome except in clinical trials, and probiotic evidence is inconsistent and limited to particular strains, conditions, and outcomes. [84][92] The listed studies on dementia, incretins and the liver, pancreatic tumor microbiomes, liver regeneration, fasting terminology, and ulcerative colitis do not directly validate a generic licensed gut-health treatment . [85][86][87][88][89]
- Mainstream view
- Mainstream medicine treats diagnosed gastrointestinal diseases with interventions supported for that specific condition; it does not recognize generic gut health as a single disease or treatment indication. Diet quality, adequate fiber when appropriate, physical activity, avoidance of unnecessary antibiotics, and management of diagnosed gastrointestinal disorders are generally emphasized. Probiotics and microbiota-based products may be appropriate in selected indications under clinical guidance, but they should not be marketed as a universal treatment for gut health. [82][89][90][91][92][93] The claim is too broad to be considered established or adequately supported.
“gut health”
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Functional medicine laboratory testing as within their scope of practice.
Functional medicine laboratory testing
No specific health claims of theirs were cross-checked against the literature.
“functional medicine”
Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Laboratory tests that a patient's doctor will not order as within their scope of practice.
Laboratory tests that a patient's doctor will not order
- Supports
- Doctors do not always order every clinically indicated laboratory or diagnostic test; systematic evidence shows substantial variation, including documented underuse of diagnostic testing in primary care. [101][102][103][104][105] Laboratory medicine literature also recognizes that appropriate test selection and ordering are important components of patient safety and quality of care. [94][95][96][97][98][99][100]
- Contradicts
- The claim is only a label and does not identify any particular test, indication, patient population, or outcome. [95][97][103] The evidence does not establish a general category of tests that doctors should order but routinely will not. Inappropriate testing is bidirectional: laboratory errors and inappropriate ordering, including unnecessary testing, are well documented. [99][101][102][104][105] Laboratory medicine reviews emphasize preventing errors and ensuring clinically appropriate testing rather than indiscriminately expanding test panels. [94][96][98]
- Mainstream view
- Clinicians should order tests when the history, examination, risk profile, and evidence-based guidelines indicate that results are likely to affect management. [103] Some tests are underused, while others are overused or poorly interpreted; whether a doctor should order a particular test depends on the clinical context. A generic list of laboratory tests that doctors supposedly will not order is not medically valid without specifying the test and indication. [95][96][97][98][99][104][105]
“labs your doctor won't order”
Manipulation
transcript · cited
The wording turns an ordinary negative or reassuring evaluation into evidence that the patient is secretly abnormal, encouraging distrust of clinicians and pursuit of more testing. Likely motive: Create anxiety and position the influencer's testing or coaching pathway as the missing solution.
“She's not normal. Her doctor just ran the wrong tests.”
transcript · cited
The description uses an unspecified trust claim to confer authority on a coaching founder without identifying relevant clinical licensure or evidence credentials. Likely motive: Increase credibility for the episode and its commercial funnel.
“one of the most trusted voices in women's gut, hormone, and metabolic health”
transcript · cited
The claim implies that a fixed set of overlooked tests reliably reveals the cause of weight-loss difficulty, without naming the tests, defining indications, or acknowledging false positives and limitations. Likely motive: Make expanded testing appear necessary and proprietary.
“The 9 labs most doctors never order — and what each one reveals that standard bloodwork completely misses”
transcript · cited
The content links hidden causes and expanded laboratory testing directly to a paid one-to-one consultation funnel. Likely motive: Convert health anxiety into booked coaching or clinical consultations.
“Want to work 1:1 with Dr. Jaban to uncover the root cause of your health challenges? Book a Call with Our Team here”
transcript · cited
The episode description does not merely educate; it directs viewers to schedule a call for individualized root-cause services. Likely motive: Generate consultation leads and downstream revenue.
“Want to work 1:1 with Dr. Jaban”
transcript · cited
Patients are framed as needing to push past doctors who decline testing, suggesting that refusal reflects failure to understand rather than clinical judgment about indications, harms, or test validity. Likely motive: Shift trust away from ordinary care and toward the influencer's services.
“what to do if they refuse”
Borrowed authority: Jillian Harbarcuk
guestCollaboration · conflation
Framed as Founder of Fueled Coaching and described as a trusted voice in women's gut, hormone, and metabolic health. Brought on to discuss Women's gut, hormone, metabolic health, weight-loss resistance, and laboratory testing. Topic sits outside the host's own scope.
“I sit down with Jillian Harbarcuk — founder of Fueled Coaching and one of the most trusted voices in women's gut, hormone, and metabolic health”
Commerce & grift map
The apparent funnel is alarming symptom framing and claims of missed causes, followed by expanded laboratory testing and a booked 1:1 root-cause consultation. No supplement or lab vendor is named, so a specific commission or referral markup cannot be established from this clip.
No paid-promotion disclosure appears on this youtube content. Viewers who arrive directly never learn the creator may be compensated by Fueled Coaching, Nine unspecified lab tests.
No on-surface paid-promotion disclosure
vendorDisclosureGap
No paid-promotion disclosure appears on this youtube content. Viewers who arrive directly never learn the creator may be compensated by Fueled Coaching, Nine unspecified lab tests.
No FTC-style compensation disclosure
compensationDisclosures · scan
A direct 1:1 consultation or coaching funnel is promoted through a booking URL.
coaching_program
Host self-funnel around guest content
guestCollaboration · selfFunnel
Host booking/consult links: https://consultation.drjabanmoore.com...
Labs pitched
- Nine unspecified lab tests
“The 9 lab tests that finally explain why”
How the money flows
- Coaching or consult upsellUndisclosed A direct 1:1 consultation or coaching funnel is promoted through a booking URL. “Want to work 1:1 with Dr. Jaban to uncover the root cause of your health challenges? Book a Call with Our Team here”
“Want to work 1:1 with Dr. Jaban to uncover the root cause of your health challenges? Book a Call with Our Team here”
Credentials & scope
Glossary: Chiropractor (“Dr.”)
Learn: Is a chiropractor a medical doctor?
Credentials and scope reflect the dossier-wide determination for this subject, drawn from the strongest verified material across every analyzed source.
Stated: none · Likely: Chiropractor
Verified against the federal provider registry: D.C. · Chiropractor · MO license 2013013283.
Jaban Moore presents as a chiropractor, a real state-regulated credential with a narrower musculoskeletal and nervous-system scope. The site nevertheless markets broad disease-cause assessment and systemic detoxification concepts, creating credential inflation through specialty overreach.
- DC, Doctor of Chiropractic
A professional chiropractic degree and license qualifying the holder to practice chiropractic within state law; it is not an MD or DO medical degree.
A state chiropractic board typically permits evaluation and treatment of musculoskeletal and related nervous-system conditions using authorized chiropractic methods, but not general internal-medicine disease management, prescription pharmacology, or broad claims to diagnose and treat systemic disease.
Permitted scope vs advertised
Missouri State Board of Chiropractic Examiners · Confidence: high
Missouri defines chiropractic as examination, diagnosis, adjustment, manipulation, and treatment using methods commonly taught in an accredited chiropractic program. The scope expressly excludes the practice of medicine and the administration or prescribing of drugs or medicine; diagnostic procedures are limited by the chiropractic scope and applicable board rules.
What this license permits
- Spinal adjustment and manipulation
- Musculoskeletal evaluation and treatment
- Soft-tissue and rehabilitative care
- Headache care within musculoskeletal scope
15 of 15 advertised activities fall outside permitted scope.
| Advertised | Verdict |
|---|---|
| H. pylori, leaky gut, and Hashimoto's almost always occur together. Rule: RSMo 331.010(1) This systemic-disease claim presents medical diagnoses and a causal association outside the affirmative chiropractic scope, which excludes the practice of medicine. | Outside scope |
| Treating H. pylori, leaky gut, and Hashimoto's together is necessary to resolve being stuck with weight loss. Rule: RSMo 331.010(1) Treating and managing gastrointestinal, autoimmune, and weight-related systemic conditions is medical treatment rather than an expressly authorized chiropractic method. | Outside scope |
| Listed service Hashimoto's Rule: RSMo 331.010(1) Hashimoto's is a systemic autoimmune medical diagnosis, not an expressly authorized chiropractic diagnosis or musculoskeletal condition. | Outside scope |
| Listed service H. pylori Rule: RSMo 331.010(1) H. pylori infection is a systemic gastrointestinal medical diagnosis outside the affirmative chiropractic scope. | Outside scope |
| Listed service Leaky gut Rule: RSMo 331.010(1) Advertising diagnosis or treatment of intestinal permeability as a disease condition is not affirmatively authorized by Missouri's chiropractic definition and falls within medical practice. | Outside scope |
| Listed service Hormone imbalance Rule: RSMo 331.010(1) Diagnosing or treating endocrine or hormonal disorders is systemic medical practice and is not affirmatively authorized for chiropractors. | Outside scope |
| Listed service Cortisol and weight gain Rule: RSMo 331.010(1) Attributing weight gain to cortisol and offering that as a health diagnosis concerns endocrine and metabolic medical management outside chiropractic scope. | Outside scope |
| Normal standard bloodwork means the doctor ran the wrong tests and the patient is not normal. Rule: RSMo 331.010(1) Overriding or criticizing medical laboratory evaluation to identify an undiagnosed systemic condition is medical diagnostic practice, not an expressly authorized chiropractic activity. | Outside scope |
| Nine additional laboratory tests explain why women's bodies stop responding to weight-loss efforts when standard bloodwork does not. Ordering or interpreting laboratory testing to diagnose unexplained metabolic or hormonal weight-loss problems is not affirmatively authorized within the chiropractic definition. | Outside scope |
| A gut-hormone connection that ordinary doctors were not trained to recognize explains these health challenges. Rule: RSMo 331.010(1) This claim asserts a medical explanation for systemic gastrointestinal, hormonal, and metabolic problems and is outside the affirmative chiropractic scope. | Outside scope |
| Listed service Women's hormones Rule: RSMo 331.010(1) Diagnosing or treating women's hormonal conditions is endocrine and reproductive medical practice, not an expressly authorized chiropractic service. | Outside scope |
| Listed service Weight loss resistance Rule: RSMo 331.010(1) Diagnosing or treating unexplained resistance to weight loss involves systemic metabolic assessment and medical management outside the affirmative chiropractic scope. | Outside scope |
| Listed service Gut health Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service Functional medicine laboratory testing Functional-medicine laboratory testing for systemic disease or metabolic conditions is not affirmatively authorized by Missouri's chiropractic scope and falls within medical diagnostic practice. | Outside scope |
| Listed service Laboratory tests that a patient's doctor will not order Offering additional tests as a means to identify medical causes that a physician allegedly failed to detect is medical diagnostic practice not affirmatively authorized for chiropractors. | Outside scope |
Sources: RSMo Section 331.010 — Practice of chiropractic, definition (official), RSMo Section 331.110 — Patient records required to be maintained (official), Missouri Board of Chiropractic Examiners — Statutes (official), Missouri Code of State Regulations, Title 20 (official)
Validated associated properties
Surfaces tied to this Doc Bro by domain, branding, or funnel routing. Third-party platforms are labeled as routes, not as owned properties.
Analyzed
- OwnedOfficial site (drjabanmoore.com)
- OwnedJaban M Moore clinic / principal site (synergizedsupps.com)
- Operated funnelPractice site (redefiningwellnesscenter.com)
- Linked entityLinked commerce or practice (m.drjaban.com)
Funnel routes (third-party)
- Hosted routeFunnel route on myshopify.com
- Hosted routeFunnel route on amazon.com
Tip the jar
Report useful? Optional tips help keep scans, archives, and literature cross-checks running. They never change conclusions.
Submission sgdx8ZyXqfolgl2TO4joN
Fight disinformation
Log a public thread where Jaban M Moore is spreading nonsense, get a copy-paste reply with this report link.
Reply snippets
Before you buy the protocol: Dr. Trust Me Bro fact-checked Jaban M Moore's claims with peer-reviewed sources, https://drtrustmebro.com/analyze/sgdx8ZyXqfolgl2TO4joN. White-coat charisma isn't evidence.
Full DTMB scan on Jaban M Moore: https://drtrustmebro.com/analyze/sgdx8ZyXqfolgl2TO4joN
Drop these in YouTube comments, Reddit threads, and forums, link back to this scan, not vibes.
Recent mentions (this doc)
- Other
Catching the Red Flags, with Michael Rubino
Interview page that features his mold and toxin claims.
- YouTube
Stop Masking Symptoms and Get to the Root Cause of Your Illness
Interview appearance with an open comment thread.
- Other
Episode 52: The Dangers of Chemical Toxicities with Jaban Moore
Podcast interview page where the pitch reaches a new audience.
- YouTube
Nervous System Dysregulation: The Invisible Barrier to Recovery
One of Jaban M Moore's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
- YouTube
How Dr. Jill Carnahan Uses Peptides for Mold, MCAS, and Chronic Illness
One of Jaban M Moore's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
Know someone who can help?
If you think someone has firsthand information about Jaban M Moore, send them an encouraging note. We email a short, respectful message with this report and clear instructions on how to write in, on the record or anonymously.
Whambulance
Challenge this scan or Wall of Fame entry for Jaban M Moore. Public log, not legal arbitration.
Public challenge log
No posted Wall of Fame challenges linked yet.
Challenges are public on the Wall of Fame card. DTMB does not remove entries for hurt feelings, primary sources or copy corrections only.
File a challenge
Include in your email:
- Doc Bro ID: LHGCVS_CZpjf-As5HKrmZ
- Wall entry: /influencer/LHGCVS_CZpjf-As5HKrmZ
- Analysis ID: sgdx8ZyXqfolgl2TO4joN
- Source: https://www.youtube.com/watch?v=mnqFUvJWjdg
- Why this entry or scan should change
- Supporting links (one per line)
- Your business email (for verified disputes)
Verified challenges are posted publicly on the report. Public log, not legal arbitration.
Citations
Peer-reviewed and index sources cited in this report.
- [1] Hypothyroidism.
- [2] Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
- [3] Hashimoto Thyroiditis.
- [4] Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis.
- [5] Nutrition and thyroid disease.
- [6] A Scoping Review on the Prevalence of Hashimoto's Thyroiditis and the Possible Associated Factors.
- [7] [Hashimoto Encephalopathy].
- [8] General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis.
- [9] Meta-analysis of the correlation between Helicobacter pylori ...
- [10] Associations of Helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis - PubMed
- [11] [PDF] Association between Helicobacter Pylori Infection and Autoimmune ...
- [12] Association of Helicobacter pylori Infection with Autoimmune ...
- [13] Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study: Randomised clinical trial: the impact of H. pylori eradication on BMI and weight
- [14] Discussion
- [15] Helicobacter pylori colonization and obesity – a Mendelian randomization study
- [16] The Effect of Helicobacter pylori Infection on Overweight
- [17] Association of obesity with Helicobacter pylori infection - NIH
- [18] Review article: associations between__Helicobacter pylori__and obesity - an ecological study
- [19] Reinforcing gut integrity: A systematic review and meta-analysis of clinical trials assessing probiotics, synbiotics, and prebiotics on intestinal permeability markers - PubMed
- [20] Interaction of obesity and infections
- [21] Effect of Helicobacter pylori Eradication on Metabolic Parameters ...
- [22] Is it safe to consume traditional medicinal plants during pregnancy?
- [23] New anabolic therapies for osteoporosis.
- [24] Micro-randomization trial design under operational constraints.
- [25] Recent advances in cell-based and cell-free therapeutic approaches for sarcopenia.
- [26] Involvement of Arabidopsis Acyl Carrier Protein 1 in PAMP-Triggered Immunity.
- [27] [Antiandrogen gynecomastia: an inescapable harm? Radiotherapy: a simple and efficient solution!].
- [28] Gynecomastia: an uncommon, destabilizing condition of the male adolescent. our therapeutic choice.
- [29] Vasopressin deficiency: a hypothesized driver of both social impairment and fluid imbalance in autism spectrum disorder.
- [30] An Endocrine Society Clinical Practice Guideline
- [31] Treatment of Symptoms of the Menopause: An Endocrine ...
- [32] An Endocrine Society* Clinical Practice Guideline - Oxford Academic
- [33] A Reappraisal: An Endocrine Society Clinical Practice Guideline
- [34] Treatment of Cushing's Syndrome: An Endocrine Society ...
- [35] The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
- [36] Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
- [37] The Diagnosis of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline
- [38] Use of the Laboratory
- [39] Approach to investigations Purchased
- [40] Decision theory for clinicians: uses and misuses of clinical tests - PubMed
- [41] Explaining laboratory test results to patients: what the clinician needs to know
- [42] A comprehensive diagnostic approach to detect underlying ...
- [43] European Society of Endocrinology Clinical Practice Guideline
- [44] Metabolic adaptation characterizes short-term resistance to weight ...
- [45] Metabolic adaptation is not a major barrier to weight-loss ...
- [46] Neuropods.
- [47] Sensory Neurons that Detect Stretch and Nutrients in the Digestive System.
- [48] Gut chemosensing: implications for disease pathogenesis.
- [49] Role of brain-gut axis in mechanism of gastrointestinal defense.
- [50] Obesity and Depression: Common Link and Possible Targets.
- [51] Grape Pomace as a Cardiometabolic Health-Promoting Ingredient: Activity in the Intestinal Environment.
- [52] The Neuro-Endo-Microbio-Ome Study: A Pilot Study of Neurobiological Alterations Pre- Versus Post-Bariatric Surgery.
- [53] Metabolic control of female puberty: potential therapeutic targets.
- [54] The gut-brain axis: interactions between enteric microbiota, central ...
- [55] Microbiota–Gut–Brain Axis: An Integrative Overview of ...
- [56] Gut–brain axis biochemical signalling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function
- [57] The microbiota–gut–brain axis: pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice
- [58] The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030.
- [59] International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause.
- [60] Female obesity and infertility: outcomes and regulatory guidance.
- [61] Tailoring transdermal estradiol dose to maximize benefits and minimize risks.
- [62] The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD).
- [63] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
- [64] Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
- [65] The G protein-coupled oestrogen receptor GPER in health and disease: an update.
- [66] Table 3.
- [67] The 2025 Menopausal Hormone Therapy Guidelines - PMC
- [68] Menopausal Hormone Therapy—Risks, Benefits and ... - PMC
- [69] State of the art in menopause: current best practice ...
- [70] Anti-obesity drug discovery: advances and challenges.
- [71] The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome.
- [72] Methionine-supplemented longevity diet increases growth hormone, GLP-1, and FGF21; reduces frailty; and promotes healthspan.
- [73] A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model.
- [74] GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.
- [75] MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.
- [76] A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.
- [77] Preclinical evaluation of candidate "kill or cure" strategies to treat MFN2-related lipodystrophy.
- [78] Pharmacologic Treatment of Overweight and Obesity in Adults
- [79] Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach
- [80] Obesity in adults: a clinical practice guideline - PMC
- [81] An Endocrine Society Clinical Practice Guideline | The Journal ...
- [82] Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses.
- [83] Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
- [84] Inflammation and immune dysfunction in Parkinson disease.
- [85] Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
- [86] Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
- [87] Multimodal decoding of human liver regeneration.
- [88] International consensus on fasting terminology.
- [89] Acute severe ulcerative colitis trials: the past, the present and the future.
- [90] AGA Clinical Practice Guidelines on the Role of Probiotics ... - PubMed
- [91] Current Treatment Options and Therapeutic Insights for ... - PMC
- [92] AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases - PubMed
- [93] AGA Technical Review on the Role of Probiotics in the ... - PMC
- [94] Errors in clinical laboratories or errors in laboratory medicine?
- [95] Phlebotomy, a bridge between laboratory and patient.
- [96] The detection and prevention of errors in laboratory medicine.
- [97] The laboratory is a key partner in assuring patient safety.
- [98] Errors in laboratory medicine and patient safety: the road ahead.
- [99] Laboratory errors and patient safety.
- [100] Laboratory Value-Based Innovation in Heart Failure Improves Patient Health-Related Outcomes.
- [101] Oral anticoagulant monitoring by laboratory or near-patient testing: what a clinician should be aware of.
- [102] Lab testing overload: a comprehensive analysis of overutilization in ...
- [103] Overtesting and undertesting in primary care: a systematic ...
- [104] The landscape of inappropriate laboratory testing: a 15- ...
- [105] Laboratory test ordering in inpatient hospitals: a systematic review ...